Professor of Molecular Medicine
Tongji University School of Life Science and Technology 1239 Siping Road Shanghai, China 200092
E-mail : Jfang@tongji.edu.cn

Education/Training

Postdoc        1997-2000, Tumor Biology/angiogenesis, Harvard Medical School, Boston, MA, USA
Ph.D.             1993-1997, Developmental Biology, Dalhousie University, Department of Biology, Halifax,
                      Nova Scotia, Canada.
Master’s.    1983-1986,    Cell Biology, Nanjing Agricultural University School of Veterinary Medicine.
                        China
Bachelor’s. 1978-1982, Veteinary Medicine, Zhejiang Agricultural University (now Zhejiang
                        University).China.

Employment
2009-present : Professor of Molecular Medicine, Tongji University, School of Life Science and
                            Technology, Shanghai, China. Deputy Director, Tongji University Suzhou Institute,  
                            Suzhou, China. Principle Investigator, Shanghai Tongji Hospital, Shanghai, China.
2008–2010 : Principle Scientist, Director of Antibody Engineering Department, Panorama Research
                        Institute, Sunnyvale, California, USA
2000-2008 : Senior Scientist, Project Leader, Cell Genesys, California, USA
1997-2000 : Research Fellow, Harvard Medical School/Children’s Hospital Boston, USA
1993-1997 : Research Assistant, Ph.D candidate, Dalhousie University, Department of Biology. Halifax,
                       Nova Scotia, Canada
1987-1993 : Lecturer, Nanjing Agricultural University School of Veterinary School, Nanjing, China

Selected Publication

1. Li D, Wei X, Xie K, Chen K, Li J, Fang J.    A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth. Br J Cancer. 2014 Jul 1;111(1):68-77
2. Li D, Xie K Xie, Ding G, Li J, Chen K, Li H, Qian J, Jiang C, Fang J. Tumor resistance to anti-VEGF therapy through up-regulation of VEGF-C expression. Cancer Lett. 2014 Apr 28;346(1):45-52.
3. Zhou S, Yang Y, Yang Y, Tao H, Li D, Zhang J, Jiang G, Fang J.    Combination Therapy of VEGF-Trap and Gemcitabine Results in Improved Anti-Tumor Efficacy in a Mouse Lung Cancer Model. PLoS One, 2013, 8 (7)
4. Liu Y, Zhang L, Wu Y, Tong T, Zhao W, Li P, Huang M, Wang W, Fang J, Wei W. Therapeutic effects of TACI-Ig on collagen-induced arthritis by regulating T and B lymphocytes function in DBA/1 mice. Eur J Pharmacol. 654(3):304-14. 2011
5. Wang D, Chang Y, Wu Y, Zhang L, Yan S, Xie G, Qin Q, Jin J, Wang W, Fang J, Wei W. Therapeutic effects of TACI-Ig on rat with adjuvant arthritis. Clin Exp Immunol. 163(2):225-34. 2011.
6. Thomas Jostock ， Zorica Dragic ，Fang J, et al., Combination of the 2A/furin technology with an animal component free cell line development platform process. Appl Microbiol Biotechnol. 2010。
7. Simmons AD, Moskalenko M, Creson J, Fang J, Yi S, Vanroey MJ, Allison JP, Jooss K. Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. Cancer Immunol Immunother. 57:1263-70. 2008.
8. Fang J, Yi S, Harding TC, Tu GH, VanRoey M, Jooss K. An antibody delivery system for regulated expression of monoclonal antibody at therapeutic level in vivo. Molecular Therapy  15:1153-1159. 2007.
9. Harper J, Yan L, Loureiro RM, Wu I, Fang J, D'Amore PA, Moses MA. Repression of vascular endothelial growth factor expression by the zinc finger transcription factor ZNF24. Cancer Research. 67:8736-8741. 2007.
10. Fang J, Qian JJ, Yi S, Harding TC, Tu GH, VanRoey M, Jooss K. Stable antibody expression at therapeutic levels using the 2A peptide. Nature Biotechnology 23:584-590. 2005.
11. Fang J and Jooss K. Rapid generation of high-level antibodies in vitro and in vivo. Discovery Medicine 5:367-370. 2005.
12. Marler JJ, Fishman SJ, Kilroy SM,    Fang J, Upton J, Mulliken JB, Burrows PE, Zurakowski D, Folkman J, Moses MA. Increased Expression of Urinary Matrix Metalloproteinases Parallels The Extent and Activity of Vascular Anomalies. Pediatrics 116:38-45. 2005.
13. Fang J, Yan L, Shing Y, Moses MA. HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. Cancer Research 61:5731-5735. 2001.
14. Fang J., Shing Y., Wiederschain D., Yan L., Butterfield C., Jackson G., Harper J., Tamvakopoulos G., Moses M.A. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proceedings of the National Academy of Sciences, USA (PNAS) 97:3884-3889. 2000.
15. Fang J. and Hall B.K. N-CAM is not required for initiation of secondary chondrogenesis: The role of N-CAM in skeletal condensation and differentiation. International Journal of Developmental Biology 43: 335-342. 1999.
16. Fang J. and Hall B.K.    Chondrogenic cell differentiation from membrane bone periostea. Anatomy and Embryology 196: 349-362. 1997.
17. Fang J. and Hall B.K.    In vitro differentiation potential of the periosteal cells from a membrane bone, the quadratojugal of the embryonic chick. Developmental Biology 180: 701-712. 1996.
18. Fang J. and Hall B.K.    Differential expression of neural cell adhesion molecule (NCAM) during osteogenesis and secondary chondrogenesis in the embryonic chick. International Journal of Developmental Biology 39: 519-528. 1995.